Changes

Before Dr. Immanuel's video went viral, the medical professional most prominently associated with HCQ in the United States was Dr. Vladimir Zelenko, a general practitioner who treats patients in the state of New York.  Since the time he first told [[Rudy Giuliani]] about [https://www.youtube.com/watch?v=1TJdjhd_XG8 the positive results he was having with HCQ + AZ + zinc], he has coauthored a preprint entitled [https://www.preprints.org/manuscript/202007.0025/v1 COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study].  The study has some problems in its current form, the most glaring of which is that "only outcome data for hospitalization and all cause death was available" for the untreated control group.<ref name =Zalenkostud>[https://www.preprints.org/manuscript/202007.0025/v1 COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study] by Martin Scholz, Roland Derwand, and Vladimir Zelenko (3 July 2020) 2020070025</ref> Ideally, one would wish to use propensity matching with these results, with age being one of the factors being accounted for, but that simply isn't possible with the data the researchers had available to them.  This having been said, the study is notable due to its incorporation of zinc, its study of outpatients, and Dr. Zelenko's prominence in the media.  So what were the results?

Before Dr. Immanuel's video went viral, the medical professional most prominently associated with HCQ in the United States was Dr. Vladimir Zelenko, a general practitioner who treats patients in the state of New York.  Since the time he first told [[Rudy Giuliani]] about [https://www.youtube.com/watch?v=1TJdjhd_XG8 the positive results he was having with HCQ + AZ + zinc], he has coauthored a preprint entitled [https://www.preprints.org/manuscript/202007.0025/v1 COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study].  The study has some problems in its current form, the most glaring of which is that "only outcome data for hospitalization and all cause death was available" for the untreated control group.<ref name =Zalenkostud>[https://www.preprints.org/manuscript/202007.0025/v1 COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study] by Martin Scholz, Roland Derwand, and Vladimir Zelenko (3 July 2020) 2020070025</ref> Ideally, one would wish to use propensity matching with these results, with age being one of the factors being accounted for, but that simply isn't possible with the data the researchers had available to them.  This having been said, the study is notable due to its incorporation of zinc, its study of outpatients, and Dr. Zelenko's prominence in the media.  So what were the results?

{{In the treatment group 4 of 141 patients were hospitalized, which was significantly less than in the untreated group with 58 of 377 patients (15.4%), (fig 2.), (OR 0.16; [95% CI, 0.06 to 0.5]; p<0.001), (table 7, fig 4). Therefore, the odds of hospitalization of treated patients were 84% less than in the untreated patients...  One of the 141 patients (0.71%) who belonged to treatment group A (age > 60 years) died after being hospitalized. This patient had a history of cancer and did only take one daily dose of the triple therapy before hospital admission. With 13 of 377 patients (3.5%, fig 3) more patients died in the untreated group (OR 0.2; [95% CI, 0.03 to 1.5]) (table 7, fig 4). The odds of all-cause death of treated patients were 80% less <nowiki>(p=0.16)</nowiki> than in the untreated group.<ref name =Zalenkostud/>}} It is a small study with serious questions concerning its control group, but Dr. Zelenko was able to find a statistically significant reduction in the hospitalization rate of patients treated with HCQ.  

{{quotebox|In the treatment group 4 of 141 patients were hospitalized, which was significantly less than in the untreated group with 58 of 377 patients (15.4%), (fig 2.), (OR 0.16; [95% CI, 0.06 to 0.5]; p<0.001), (table 7, fig 4). Therefore, the odds of hospitalization of treated patients were 84% less than in the untreated patients...  One of the 141 patients (0.71%) who belonged to treatment group A (age > 60 years) died after being hospitalized. This patient had a history of cancer and did only take one daily dose of the triple therapy before hospital admission. With 13 of 377 patients (3.5%, fig 3) more patients died in the untreated group (OR 0.2; [95% CI, 0.03 to 1.5]) (table 7, fig 4). The odds of all-cause death of treated patients were 80% less <nowiki>(p=0.16)</nowiki> than in the untreated group.<ref name =Zalenkostud/>}}

It is a small study with serious questions concerning its control group, but Dr. Zelenko was able to find a statistically significant reduction in the hospitalization rate of patients treated with HCQ.  

Dr. Zelenko is another figure who is too prominent to be ignored.   

Dr. Zelenko is another figure who is too prominent to be ignored.